Title |
Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas
|
---|---|
Published in |
Cancer Treatment Reviews, May 2015
|
DOI | 10.1016/j.ctrv.2015.05.007 |
Pubmed ID | |
Authors |
D. Pérez-Callejo, J. González-Rincón, A. Sánchez, M. Provencio, M. Sánchez-Beato |
Abstract |
Anti-CD20 monoclonal antibodies (mAbs) have improved patient's survival with Non-Hodgkin Lymphoma, when combined with chemotherapy. Several mechanisms of action have been reported, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and induction of apoptosis. Despite the large amount of studies and published data, the role each mechanism played in vivo is not fully understood. Furthermore, the reason why a significant percentage of patients are refractory or resistant remains unknown. Several activated intracellular signaling pathways have been implicated in the mechanisms of resistance of rituximab. In the present manuscript, we review those mechanisms and new anti-CD20 mAbs, as well as the efforts being accomplished to overcome it, focusing on new drugs targeting pathways implicated in resistance to rituximab. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | 1% |
Unknown | 79 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 16 | 20% |
Student > Ph. D. Student | 13 | 16% |
Researcher | 13 | 16% |
Student > Master | 12 | 15% |
Other | 5 | 6% |
Other | 10 | 13% |
Unknown | 11 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 25 | 31% |
Medicine and Dentistry | 16 | 20% |
Biochemistry, Genetics and Molecular Biology | 10 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
Chemistry | 3 | 4% |
Other | 8 | 10% |
Unknown | 12 | 15% |